Working Group 4 was commissioned by the HBD steering committee to promote improvements in “regulatory convergence and communication.” This concept paper provides information on the WG4 mission and activities as envisioned by its members in response to the HBD steering committee’s direction and guidance to the working group.
The differences in medical device regulations between the US and Japan provide an opportunity to improve the timely availability of innovative medical devices to patients who would most benefit from them in the course of their medical treatment. Whereas the GHTF (Global Harmonization Task Force) focuses its activities on the development of harmonized regulatory guidance and broader global harmonization of medical device regulations, more specific and experience-based studies need to be conducted to find solutions to the real problems that the US and Japan specifically share in providing timely approvals of medical devices. The fundamental purpose of HBD is to seek convergence of regulatory requirements and practices through concrete experience “by doing” rather than through theory. HBD is intended to offer a suitable venue for such studies. Under the direction of the HBD steering committee, “regulatory convergence and communication” was identified as critical to the implementation of harmonization initiatives and was assigned to WG4. Issues associated with regulatory convergence and communication will likely be identified within other HBD working groups as well. The steering committee will therefore coordinate work between the groups on common issues. The HBD working groups will work jointly and collaborate to find solutions to the shared issues. The concepts and planning of WG4 as described above are subject to change by the steering committee and by input from WG4, other HBD working groups and stakeholders.
The mission of WG4 is to facilitate the timely global introduction of new medical technologies by identifying and addressing specific regulatory barriers through proof-of-concept projects. The scope of WG4 is to improve administrative practices within the context of existing regulations with the goal of convergence between Japanese and US practices and improved communication between stakeholders. WG4 will also look for opportunities for possible future revisions of those existing regulations where changes in administrative practices are insufficient to promote regulatory convergence.
The specific aims are:
The expected deliverables include:
Membership selection will consider the general principles of HBD for symmetry and balance between the US and Japan, among government, academia and industry, and among all stakeholders and constituencies.
The chairmanship of WG4 will be held jointly by designated representatives of FDA and MHLW. Chairmanship by regulators is justified because the issues discussed in WG4 are primarily related to the regulatory approach by authorities. Moreover, regulators are more aware of agency policies and procedures, therefore any recommendations from WG4 will be more conducive to implementation in both agencies.
Possible regulatory target areas for examination include:
Business plans and milestones for 2006-2008 include:
In summary, this concept paper will guide WG4 mission and activities to promote improvements in “regulatory convergence and communication.”
Updated January 14, 2008
CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page
Center for Devices and Radiological Health / CDRH